Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2896-3
Published Online: 2015-11-11
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Daga, Haruko
Takeda, Koji
Okada, Hideaki
Miyazaki, Masaki
Ueda, Shinya
Kaneda, Hiroyasu
Okamoto, Isamu
Yoh, Kiyotaka
Goto, Koichi
Konishi, Koichi
Sarashina, Akiko
Tanaka, Tetsuya
Kaiser, Rolf
Nakagawa, Kazuhiko
Text and Data Mining valid from 2015-11-11